Who is sponsoring NCT07533981?

NCT07533981 is sponsored by Alexei Ouriadov.

What drugs are being tested in NCT07533981?

Interventions in NCT07533981: Hyperpolarized Xenon MRI.

What condition does NCT07533981 study?

NCT07533981 studies Healthy Volunteers - Male and Female.

Is NCT07533981 still recruiting?

NCT07533981 is currently not yet recruiting. Last updated 16 April 2026.

Last reviewed 2026-04-16 · How we verify

NCT07533981

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

¹²⁹Xe(XENON) MRI Program

Not yet recruiting NA Last updated 16 April 2026

What this trial tests

NA trial testing Hyperpolarized Xenon MRI in Healthy Volunteers - Male and Female in 200 participants. Not yet recruiting.

Timeline

1 July 2026

Primary endpoint
30 December 2030

30 April 2031

Quick facts

Lead sponsor	Alexei Ouriadov
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	1 July 2026
Primary completion	30 December 2030
Estimated completion	30 April 2031
Sites	1 location across Canada

Drugs / interventions tested

Hyperpolarized Xenon MRI

Conditions studied

Healthy Volunteers - Male and Female — all drugs for Healthy Volunteers - Male and Female →

Sponsor

Alexei Ouriadov

Who can join

Adults 18 to 85, any sex, with Healthy Volunteers - Male and Female. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Healthy volunteers aged 18 to 85 will undergo hyperpolarized Xenon-129 (¹²⁹Xe) MRI and pulmonary function testing. The study aims to develop evaluation tools for ventilation defect percent (VDP), signal-to-noise and contrast-to-noise ratios (SNR/CNR) of ¹²⁹Xe dissolved-phase images, and spectroscopy-based analysis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Alexei Ouriadov trials

Trials by the same sponsor.

NCT07305532 — ¹⁹F (Perfluoropropane) MRI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07533981 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alexei Ouriadov
Last refreshed: 16 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07533981.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing